References
- Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49:243-54
- Rosser T, Panigrahy A, McClintock W. The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol 2006;13:27-36
- Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008;372:657-68
- Kingswood C, Bolton P, Crawford P, et al. The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol 2015;20:296-308
- TSA Tuberous Sclerosis Alliance. What is TSC? Silver Spring, Maryland, USA: National Tuberous Sclerosis Association Inc., 2013. http://www.tsalliance.org/pages.aspx?content =2. Accessed June 1, 2015
- TSA Tuberous Sclerosis Alliance. Consultation on the United Kingdom plan for rare diseases: submission from the Tuberous Sclerosis Association. London: Tuberous Sclerosis Alliance, 2012. URL:http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ved=0CCIQFjAA&url=http://www.tuberous-sclerosis.org/_literature_124492/TSA_Publications_-_Consultation_on_the_UK_Plan_for_Rare_Diseases&ei=9Y5cVf7-B8jwUqjAgegB&usg=AFQjCN. Published 2012. Accessed June 1, 2015
- van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-8. http://www.ncbi.nlm.nih.gov/pubmed/9242607. Accessed November 13, 2015
- Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90
- European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15. http://www.ncbi.nlm.nih.gov/pubmed/8269512. Accessed October 1, 2015
- Sancak O, Nellist M, Goedbloed M, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Gene. 2005;13:731-41
- Niida Y, Lawrence-Smith N, Banwell A, et al. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat 1999;14:412-22
- Kozlowski P, Roberts P, Dabora S, et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 2007;121:389-400
- Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999;64:1305-15
- Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80
- Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56
- Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007;9:88-100
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2013;381:125-32
- O’Callaghan FJ, Noakes MJ, Martyn CN, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004;94:853-7
- Cook JA, Oliver K, Mueller RF, et al. A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 1996;33:480-4. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1050634&tool=pmcentrez&rendertype=abstract. Accessed November 17, 2015
- Henske EP, Ewalt DH, Bissler JJ. Renal manifestations in tuberous sclerosis complex. Silver Spring, Maryland: Tuberous Sclerosis Alliance, 2006. http://www.tsalliance.org/documents/Renal Manifestations in TSC.pdf. Accessed February 2, 2016
- Pirson Y. Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action. Nephrol Dial Transplant 2013;28:1680-5
- Rouvière O, Nivet H, Grenier N, et al. [Guidelines for the management of tuberous sclerosis complex renal disease]. Prog Urol 2012;22:367-79
- Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 2011;118:e15-e20
- Vekeman F, Magestro M, Karner P, et al. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J Med Econ 2015;18:1060-70. http://www.tandfonline.com/doi/full/10.3111/13696998.2015.1075995. Accessed November 16, 2015
- Ewalt DH, Sheffield E, Sparagana SP, et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol 1998;160:141-5. http://www.ncbi.nlm.nih.gov/pubmed/9628635. Accessed November 16, 2015
- Northrup H, Koenig MK, Pearson DA, et al. Tuberous Sclerosis Complex. GeneReviews® [Internet]. Seattle (WA): University of Washington, 2015. http://www.ncbi.nlm.nih.gov/books/NBK1220/. Accessed November 13, 2015
- Shepherd CW, Gomez MR, Lie JT, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991;66:792-6. http://www.ncbi.nlm.nih.gov/pubmed/1861550. Accessed November 16, 2015
- Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2013;381:817-24
- Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 2006;70:1777-82
- Eijkemans MJC, van der Wal W, Reijnders LJ, et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis 2015;66:638-45
- Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97
- Webb DW, Kabala J, Osborne JP. A population study of renal disease in patients with tuberous sclerosis. Br J Urol 1994;74:151-4. http://www.ncbi.nlm.nih.gov/pubmed/7921930. Accessed October 16, 2015
- Laass MW, Spiegel M, Jauch A, et al. Tuberous sclerosis and polycystic kidney disease in a 3-month-old infant. Pediatr Nephrol 2004;19:602-8
- Bret PM, Bretagnolle M, Gaillard D, et al. Small, asymptomatic angiomyolipomas of the kidney. Radiology 1985;154:7-10
- Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49:255-65
- García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1873548&tool=pmcentrez&rendertype=abstract. Accessed September 4, 2015
- Williams T, van Staa T, Puri S, et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv drug Saf 2012;3:89-99
- Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36
- Ipsos Mori. GP Patient Survey - National Summary Report. London: Ipsos Mori, 2014. http://gp-survey-production.s3.amazonaws.com/archive/2014/July/1301375001_Y8W2 National Summary Report_FINAL v1.pdf. Accessed August 6, 2015
- NHS Business Services Authority. NHS Drug Tariff. Surrey, UK: NHS Business Services Authority, 2102. http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx. Accessed August 1, 2015
- Department of Health. NHS Reference Costs. London: Department of Health, 2015. https://www.gov.uk/government/collections/nhs-reference-costs. Accessed August 1, 2015